Package:
I.V. INFUS. (liposome inject.): 1. Dosage: Ovarian Cancer Patients: Doxil should be administered intravenously at a dose of 50 mg/m² at an initial rate of 1 mg/minute to minimize the risk of infusion reactions. If no infusion-related AEs are observed, the rate of infusion can be increased to complete administration of the drug over one hour. The patient should be dosed once every 4 weeks, for as long as the patient does not progress, shows no evidence of cardiotoxicity, and continues to tolerate treatment. A minimum of 4 courses is recommended because median time to response in clinical trials was 4 months. To manage adverse events such as PPE, stomatitis, or hematologic toxicity the doses may be delayed or reduced. Aids KS Patients: Doxil should be administered intravenously at a dose of 20 mg/m² over 30 minutes, once every 3 weeks, for as long as patients respond satisfactorily and tolerate treatment. Prescribing Restrictions:
Indications:
Monotherapy in metastatic breast cancer, where there is an increased cardiac risk. First or second line therapy of AIDS-related Kaposi’s sarcoma in patients with low cd 4 counts and extensive mucocutaneous or visceral disease. Treatment of patients with metastatic carcinoma of ovary who are refractory to both paclitaxel and platinum-based chemotherapy regimens and who may also be refractory to topotecan. Refractory is defined as a patient having progressive disease while on treatment, or within 6 months of completing treatment. Contra-Indications:
See prescribing information for full details. Special Precautions:
See prescribing information for full details. Side Effects:
See prescribing information for full details. Drug Interactions:
Cyclophosphamide.
